Dose-effect and dose-response relationships for lead in children.
Lead absorption and prevention of the serious effects of lead re-examined from the viewpoints of the critical organ and clinical effect concepts and the associated dose-effect and dose-response relationships. If the critical organ is the first affected and the critical effect is the first measurable adverse effect, intervention on this basis should prevent the occurrence of later, more serious effects. In the range of lead absorption of greatest current pediatric concern (blood lead in the range of 50 to 80 mug/dl), blood lead values are not a good predictor of critical effect, whereas chelatable lead is significantly and linearly related to evidence of critical effect on hemoglobin synthesis in the bone marrow. Erythrocyte protoporphyrin and delta-aminolevulinic acid and coproporphyrin in urine are indicators of this effect. The dose-response concept provides a better way of viewing the relationship between blood lead and measures of adverse effect than do the classifications of "sensitivity," "specificity", "false negatives," and "false positives," which are often employed in the evaluation of screening tests. The dose-response concept recognizes the uniqueness of the individual and the presence of susceptible and resistant individuals in heterogeneous population groups. With the dose-response concept, individuals may be identified as reactors or nonreactors, according to whether they exhibit a particular effect. Among the various indicators of lead's critical (or first) effect on hemoglobin synthesis, erythrocyte protoporphyrin potentially is the most practical for monitoring children at high risk for plumbism.
D000293:Adolescent; D000622:Aminolevulinic Acid / Q000652:urine; D002648:Child; D003306:Coproporphyrins / Q000652:urine; D004305:Dose-Response Relationship, Drug; D004492:Edetic Acid / Q000627:therapeutic use; D006454:Hemoglobins / Q000096:biosynthesis; D006801:Humans; D007854:Lead / Q000097:blood* / Q000652:urine; D007855:Lead Poisoning / Q000188:drug therapy; D000623:Porphobilinogen Synthase / Q000097:blood; D011524:Protoporphyrins / Q000097:blood
D003306:Coproporphyrins; D006454:Hemoglobins; D011524:Protoporphyrins; D007854:Lead; D000622:Aminolevulinic Acid; D004492:Edetic Acid; D000623:Porphobilinogen Synthase